ArticleRisk management and healthcare policy2025
Risk Factors and Clinical Management Strategies for Bloodstream Infections in Pediatric Hematological Malignancies.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for antibiotic resistance and 30-day mortality among adult patients with acute leukemia and Escherichia coli bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chemotherapy remains the primary treatment for haematological malignancies (HMs). While recent therapeutic advances have improved patient survival, treatment-induced immunosuppression and prolonged neutropenia significantly elevate the risks of bloodstream infection (BSI), contributing to higher mortality. This study identifies risk factors for BSI in pediatric HM patients, aiming to establish evidence-based protocols for infection prevention and risk stratification, thereby informing targeted healthcare policies to reduce complications and improve treatment outcomes. Patients and Methods: We retrospectively analyzed 682 pediatric HM patients presenting with fever at our institution, including 98 BSI-confirmed cases.Results were statistically compared across multiple aspects. Results: Pediatric HM patients with bloodstream infection showed significantly higher AML prevalence (47.96% vs 33.22%, Conclusion: To reduce BSI complications in pediatric HM patients, we recommend implementing risk-stratified temperature protocols and strict neutropenia control (≤7 days), emphasizing rigorous clinical criteria for invasive procedures (PICC). These findings provide an evidence base for healthcare policies aimed at reducing infection-related mortality through optimized treatment protocols and enhanced clinical care standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.